In this issue of Blood, Lu et al describe the cooperation between an orally bioavailable mouse double minute 2 (MDM2) antagonist (RG7112) and the pegylated interferon α (Peg-IFNα 2a) to target JAK2V617F hematopoietic progenitors and stem cells. Their work provides a rationale for the treatment of patients suffering from myeloproliferative neoplasms (MPNs).1 © 2014 by The American Society of Hematology.
CITATION STYLE
Plo, I. (2014, July 31). p53 at the crossroads of MPN treatment. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2014-06-579623
Mendeley helps you to discover research relevant for your work.